Every Form 4 that Incyte Corp (INCY) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow INCY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INCY filings page.
BAKER BROS. ADVISORS LP reported acquisition or exercise transactions in this Form 4 filing.
INCYTE CORP director representative entities reported a small equity award related to board compensation. A single grant of 421 restricted stock units (RSUs) of Common Stock was issued under Incyte's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees of $40,500 for Julian C. Baker’s board service. The RSUs are fully vested and are reported for each of 667, L.P. and Baker Brothers Life Sciences LP because each fund has an indirect pecuniary interest, while Baker Bros. Advisors LP has voting and dispositive power over the compensation shares pursuant to its policies.
HARRIGAN EDMUND reported acquisition or exercise transactions in this Form 4 filing.
INCYTE CORP director Edmund Harrigan received 269 shares of common stock as a fully vested restricted stock award. The shares were issued under Incyte’s Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees, pursuant to a pre-arranged Rule 10b5-1 election. After this grant, he directly holds 21,122 shares of common stock, which includes 2,518 shares issuable from previously reported restricted stock units that have not yet vested.
INCYTE CORP director Paul J. Clancy received 265 shares of common stock as a fully vested restricted share award. The grant was made under Incyte's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees, pursuant to an election intended to comply with Rule 10b5-1. Following this compensation-related acquisition, he holds 23,741 shares directly, including 2,518 shares of common stock issuable from previously reported restricted stock units that have not yet vested.
INCYTE CORP executive reports routine tax withholding share disposition. EVP, GM Dermatology US Matteo Trotta had 537 shares of common stock withheld at a price of $92.23 per share to cover tax obligations tied to previously granted restricted stock units. After this automatic withholding, he directly holds 14,882 common shares. Footnotes state that this figure includes 11,160 shares underlying restricted stock units that are not yet vested.
INCYTE CORP President, R&D Pablo J. Cagnoni exercised stock options and then sold shares in a routine liquidity transaction. He exercised options to acquire 7,166 shares of common stock at $61.18 per share and 11,501 shares at $64.25 per share, totaling 18,667 shares. On the same day, he sold 18,667 common shares at an average price of $94.24 per share. After these transactions, his reported direct ownership was 234,800 common shares, which the notes state includes 229,661 shares underlying previously reported unvested restricted and performance stock units.
INCYTE CORP President, R&D Pablo J. Cagnoni reported multiple equity transactions. On February 19, 2026, he exercised employee stock options into 13,093 and 5,575 shares of common stock at exercise prices of $61.76 and $61.18 per share, respectively, through derivative conversions.
He then executed an open-market sale of 18,668 shares of common stock at an average price of $100.91 per share. After these transactions, he directly owned 234,800 shares of common stock, plus remaining stock options, and had an additional 229,661 shares tied to unvested restricted and performance stock units.
Incyte Corporation executive Michael James Morrissey reported a small share withholding related to equity compensation. On February 2, 2026, 185 shares of Incyte common stock were withheld at $102.67 per share to cover tax obligations from previously granted restricted stock units.
After this withholding, Morrissey beneficially owns 34,065 shares of Incyte common stock directly. This total includes 22,560 shares tied to previously reported restricted stock units and earned performance stock units that are not yet vested, reflecting ongoing equity-based compensation rather than an open-market sale.
Incyte Corporation executive Heeson Lee reported a routine tax-related share transaction. On 02/02/2026, 111 shares of Incyte common stock were withheld automatically at a price of $102.67 per share to satisfy tax obligations from settling previously granted restricted stock units.
After this withholding, Lee beneficially owned 38,041 shares of Incyte common stock directly. This total includes 33,496 shares that are issuable from earlier reported restricted stock units that have not yet vested, reflecting a significant portion of equity held in unvested awards.
Incyte Corporation executive Heeson Lee reported a stock-based compensation grant. On January 16, 2026, Lee received 8,911 shares of common stock, awarded in the form of restricted stock units (RSUs) at a price of $0 per share.
The RSUs will vest 25% each year over four years and can be settled only in shares of Incyte common stock on a one-for-one basis. After this grant, Lee beneficially owns 38,152 shares of common stock, including an aggregate of 35,078 shares underlying previously reported RSUs that have not yet vested.
Incyte Corporation reported a new stock option grant to a senior executive. President of R&D Pablo J. Cagnoni received an employee stock option to purchase 28,475 shares of Incyte common stock at an exercise price of $106.21 per share, effective January 16, 2026.
The option was granted at no cost to the executive and is held directly. Beginning January 16, 2026, the award becomes exercisable in 37 installments, with the first 25% vesting on July 15, 2026 and the remaining portion vesting monthly over the following three years. After this grant, Cagnoni beneficially owns 28,475 derivative securities in the form of these options.
Incyte Corporation executive Steven H. Stein, EVP & Chief Medical Officer, reported a new stock option grant. On January 16, 2026, he received an employee stock option to purchase 19,932 shares of Incyte common stock at an exercise price of $106.21 per share. These options begin to become exercisable in 37 installments starting January 16, 2026.
The vesting schedule provides that the first 25% of the options vest on July 15, 2026, with the remaining options vesting in monthly installments over the following three years. The option expires on January 15, 2036, giving a ten-year term from the grant date.
Incyte Corporation executive Issa Mohamed Khairie, EVP and Head of US Oncology, reported a new stock option grant. On January 16, 2026, he received an employee stock option giving the right to buy 14,237 shares of Incyte common stock at an exercise price of $106.21 per share, expiring on January 15, 2036. Following this grant, he beneficially owned 14,237 derivative securities directly.
The options begin to become exercisable in 37 installments starting January 16, 2026. The first 25% will vest on July 15, 2026, with the remaining portion vesting monthly over the next three years, tying the long-term incentive to continued service and performance.
Incyte Corporation executive Matteo Trotta, EVP and GM of Dermatology US, reported a grant of employee stock options on common stock. On January 16, 2026, he received 8,542 stock options with an exercise price of $106.21 per share and no cost for the option grant itself. These options expire on January 15, 2036.
Beginning January 16, 2026, the options become exercisable in 37 installments, with the first 25% vesting on July 15, 2026 and the remaining options vesting monthly over the following three years. After this grant, Trotta beneficially owns 8,542 derivative securities directly in the form of these options.
Incyte Corporation’s Principal Accounting Officer, Tray Thomas, reported receiving an employee stock option grant under the company’s equity plan. On January 16, 2026, Thomas was awarded options to purchase 2,425 shares of Incyte common stock at an exercise price of $106.21 per share.
According to the filing, these options begin to vest on January 16, 2026 in 37 installments. The first 25% of the grant vests on July 15, 2026, and the remaining options vest monthly over the following three years. All 2,425 derivative securities are held directly by the reporting officer.
Incyte Corporation executive Patrick A. Mayes, EVP & Chief Scientific Officer, reported a grant of 4,218 employee stock options on January 16, 2026. These options have an exercise price of $106.21 per share and give the right to buy Incyte common stock.
Beginning January 16, 2026, the options become exercisable in 37 installments, with the first 25% vesting on July 15, 2026 and the remaining portion vesting monthly over the following three years, and they expire on January 15, 2036. After this award, Mayes beneficially owns 4,218 derivative securities directly.
Incyte Corporation EVP Michael James Morrissey, Head of Tech. Operations, reported routine equity compensation activity in company common stock. On January 16, 2026, he received an award of 7,426 restricted stock units (RSUs), which will vest in four equal annual installments of 25% and can be settled one-for-one in common shares. On January 20, 2026, 429 shares were automatically withheld by Incyte at $102.62 per share to cover tax obligations tied to previously granted RSUs. After these transactions, Morrissey beneficially owned 34,250 shares of common stock, including 25,198 shares underlying unvested RSUs and earned performance stock units.
Incyte executive Issa Mohamed Khairie reported two stock transactions. On 01/06/2026, 8,264 shares of common stock were automatically withheld by the issuer at a price of $106.66 to cover tax obligations tied to previously granted restricted stock units. On 01/07/2026, Khairie sold 10,856 shares of Incyte common stock at a price of $109.07 per share in an open market transaction. After these transactions, Khairie directly beneficially owned 66,132 shares of common stock, which includes shares issuable from previously reported RSUs that have not yet vested.
Incyte Corporation executive Steven H. Stein, EVP & Chief Medical Officer, reported selling 15,634 shares of Incyte common stock on January 5, 2026 at a price of $101.7 per share. The transaction was reported as a direct sale on a Form 4 insider filing.
After this sale, Stein beneficially owned 34,203 shares of Incyte common stock. This amount includes shares issuable under previously reported restricted stock units and earned performance shares that have been granted but have not yet vested.
Incyte Corporation’s Executive Vice President and Head of Technical Operations reported several sales of company common stock. On December 16, 2025, the officer sold 833 shares at $97.42 per share and 53,175 shares at $97.29 per share. On December 17, 2025, the officer sold 4,323 shares at $97.26 per share. After these transactions, the officer reported beneficial ownership of 27,507 shares, which the filing explains includes shares issuable under previously reported restricted stock units and earned performance stock units that have not yet vested.
Incyte Corporation reported an insider stock sale by its Executive Vice President and Chief Scientific Officer. On 12/10/2025, the officer sold 5,553 shares of common stock at $95.58 per share. On 12/11/2025, they sold another 255 shares at $94.94 per share. After these transactions, the reporting person directly beneficially owns 60,011 common shares. A footnote also identifies 59,858 additional shares of common stock issuable under previously reported restricted stock units that have not yet vested.
Incyte Corp’s Executive Vice President & Chief Medical Officer reported several stock transactions in early December 2025. On 12/01/2025, the insider sold 2,559 shares of common stock at $102.96 per share and had 100,327 shares beneficially owned afterward. That same day, 17,093 shares were withheld by the company at $102.04 per share to cover tax obligations tied to previously reported restricted stock units and performance shares.
On 12/02/2025, the insider sold an additional 20,105 shares at $102.51 per share, leaving 63,129 shares beneficially owned. According to the explanation, this total includes shares issuable under restricted stock units and earned performance shares that have not yet vested.
Incyte Corporation (INCY) reported insider stock transactions by its Principal Accounting Officer on a Form 4. The officer sold 169 shares of common stock on 11/21/2025 at $102 per share and 600 shares on 11/24/2025 at $103 per share. After these sales, the officer directly owned 23,573 shares of Incyte common stock.
The filing also notes that, including a July 15, 2025 grant, the officer holds an aggregate of 15,166 shares of common stock issuable from previously reported restricted stock units that have not yet vested. These transactions reflect personal trading activity by a company officer and ongoing equity-based compensation.
Incyte Corporation’s EVP & General Counsel filed a Form 4 reporting a small insider transaction. On 11/17/2025, the executive exercised an employee stock option to acquire 278 shares of common stock at $64.25 per share and on the same day sold 278 shares at $104.36 per share. After these transactions, the executive directly owned 26,569 shares of Incyte common stock and held 8,883 employee stock options. The filing also notes 25,913 shares of common stock underlying previously reported restricted stock units and earned performance units that are issuable but not yet vested.
Incyte Corporation (INCY) filed a Form 4 disclosing an insider sale. A director reported selling 187,500 shares of common stock on 11/10/2025 at a price of $105.46 per share. Following this transaction, the reporting person beneficially owns 329,646 shares, held directly.
The filing notes that this total includes 73,486 shares issuable from previously reported RSUs and earned performance shares that have not yet vested. No derivative securities were reported in Table II for this transaction. This is a routine insider ownership update and does not by itself indicate changes in company operations or strategy.
Incyte Corp (INCY): Form 4 insider activity. The company’s EVP & Chief Medical Officer reported option exercises and a same‑day sale on 11/05/2025.
The executive exercised options for 1,194 shares at $83.83, 2,995 shares at $95.76, and 1,044 shares at $95.76, then sold 5,233 shares at $102.20. Following these transactions, the executive beneficially owns 102,886 shares directly.
Footnotes note that 100,327 shares are issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. The exercised options were from grants that became exercisable per their original vesting schedules.
Incyte (INCY) insider activity: The company’s EVP & General Counsel reported a same‑day option exercise and sale on 11/04/2025. He exercised 598 employee stock options at $58.06 per share and sold 598 common shares at $101.36 per share.
Following these transactions, he directly owned 26,569 common shares. He also held 13,765 derivative securities (employee stock options) after the activity. In addition, the filing notes 25,913 shares of common stock are issuable pursuant to previously reported restricted stock units and earned performance units that have not vested.
Incyte Corp (INCY) reported an insider transaction on Form 4. The company’s EVP, Head of Incyte Intl, sold 3,074 shares of common stock on 11/03/2025 at $94.02 per share.
Following the sale, the reporting person beneficially owned 29,241 shares directly. This figure includes 26,167 shares issuable pursuant to previously reported RSUs that have not vested.
Incyte (INCY) reported an insider transaction by its EVP & General Counsel. On 10/15/2025, the officer exercised 277 employee stock options at a $64.25 exercise price and sold 277 shares of common stock at $85.13.
Following the transactions, the officer beneficially owned 26,569 shares directly, which includes an aggregate of 25,913 shares issuable from previously reported unvested RSUs and earned performance units. Derivative securities beneficially owned after the transactions totaled 9,161 options. The reported option grant expires on 07/14/2034 and vests in installments as disclosed.
Sheila A. Denton, EVP & General Counsel of Incyte Corp (INCY), reported multiple transactions on 10/02/2025 and 10/03/2025. She exercised employee stock options for 599 shares at an exercise price of $58.06 and acquired 599 common shares via that exercise. Concurrently, she sold a series of shares: 599 at $87.65, 3,130 at $86.28, and 3,501 at $85.54, reducing her direct common stock holdings to 26,569 shares. The filing notes 3,130 shares were withheld to satisfy tax obligations and that 25,913 shares remain issuable under previously reported restricted stock units and earned performance units that have not vested. After the reported activity, she holds 14,363 option-based derivative securities and 26,569 direct common shares.
Patrick A. Mayes, EVP & Chief Scientific Officer of Incyte Corp (INCY), reported a disposition of company shares on 10/01/2025. The filing shows 1,569 shares of common stock were disposed of at a price of $86.70 per share under transaction code F, and the reporting person remains the beneficial owner of 65,819 shares following the transaction. The filing explains the 1,569 shares represent shares withheld automatically by the issuer to satisfy tax-withholding obligations associated with the settlement of previously reported restricted stock units.
The report also notes that of the remaining position, 59,858 shares are issuable pursuant to previously reported restricted stock units that have not vested. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 10/03/2025.
Heeson Lee, EVP and Head of Incyte International, filed a Form 4 reporting changes in beneficial ownership of INCY common stock. On 10/01/2025 the filing shows 463 shares were disposed of (reported under Code F) at a price of $86.7 per share to satisfy tax withholding obligations tied to previously granted restricted stock units. After the reported transaction the filing shows beneficial ownership of 32,315 shares; the filer discloses that this total includes 26,167 shares issuable under previously reported unvested RSUs. The form is signed by an attorney-in-fact on 10/03/2025.
Incyte Corp director Paul J. Clancy acquired 285 shares of Incyte common stock on 09/30/2025 at a price of $84.81 per share through restricted shares issued in lieu of quarterly director retainer fees under the company’s Amended and Restated 2010 Stock Incentive Plan; those restricted shares are reported as fully vested.
Following this transaction, the reporting person beneficially owns 23,235 shares in total, which includes an aggregate of 2,518 shares issuable upon previously reported restricted stock units that have not vested.
Edmund Harrigan, a director of Incyte Corp (INCY), acquired 289 shares of common stock on 09/30/2025 at a price of $84.81 per share. The shares were issued as restricted shares under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of a quarterly director retainer, and the filing states the restricted shares are fully vested. After this transaction, the reporting person beneficially owns 20,608 shares, which includes 2,518 shares issuable under previously reported restricted stock units that have not vested. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.
Incyte Corp (INCY) reported equity awards to David H. Gardner, EVP and Chief Strategy Officer, on 09/22/2025. The filing shows a grant of 9,429 restricted stock units (RSUs) that vest 25% annually over four years and are settled one-for-one in common stock. The report also lists 23,573 performance shares that can pay up to 200% of one share based on relative total shareholder return versus a fixed peer group over a three-year performance period beginning 01/01/2025, with earned shares vesting on the third anniversary. Additionally, 42,899 employee stock options were granted at an $84.73 exercise price, exercisable in 37 installments with the first 25% after one year and monthly vesting thereafter, expiring 09/22/2035. The filing shows the reporting person beneficially owned 9,429 common shares and had derivative interests underlying 23,573 performance shares and 42,899 options following the grants.
Sheila A. Denton, EVP & General Counsel of Incyte Corporation (INCY), reported multiple transactions on 09/16/2025. The Form 4 shows a non-derivative acquisition of 278 shares of common stock at $64.25 and a non-derivative disposition of 278 shares at $83.15, leaving her with 33,200 shares beneficially owned after the sale. The filing also reports exercise of 278 employee stock options with a $64.25 exercise price, resulting in 278 underlying shares and total derivative holdings of 9,438 option-related shares exercisable through 07/14/2034. The filing discloses that 32,544 of the reported common shares are issuable under previously reported restricted stock units and earned performance units that have not vested.